Sign In
Buy GLP
$49.26
+1.26 (+2.63%)
At Close: Jun 02, 2026
16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: M
Amazon Pharmacy to Offer Eli Lilly and Company's New GLP-1 Pill Foundayo via Same-Day Delivery
07:49am, Thursday, 09'th Apr 2026
SEATTLE--(BUSINESS WIRE)--Amazon Pharmacy (NASDAQ: AMZN), a full-service digital pharmacy that offers fast medication delivery directly to customers' homes, now offers Eli Lilly and Company's recently
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.
06:45am, Thursday, 09'th Apr 2026
Foundayo is now available via LillyDirect ® and telehealth providers and is shipping to retail pharmacies nationwide Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day wi
Oral GLP-1 Is Here - Have Credit Markets Caught Up?
02:15am, Thursday, 09'th Apr 2026
For the past two years, GLP-1 medications have been a fixture of consumer trend analysis, discussed by everyone from CNBC to sell-side strategists to management consultants. Real apparel expenditure o
WASHINGTON, April 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the preven
Hims & Hers price target slashed amid GLP-1 transition
12:26pm, Wednesday, 08'th Apr 2026
Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple compression and near-term earnings pressures. Shares of Hims & Hers traded hands at abou
Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
07:00am, Tuesday, 07'th Apr 2026
Novo Nordisk's new Wegovy GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections. CNBC spoke with five U.S. patie
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
07:00am, Tuesday, 07'th Apr 2026
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and oth
Kailera Therapeutics Pursues IPO On Promising GLP-1 Trial Results
01:20pm, Monday, 06'th Apr 2026
Kailera Therapeutics is targeting an IPO to fund GLP-1-based obesity treatments, led by ribupatide, with positive efficacy data versus tirzepatide. KLRA is well-capitalized with $546 million in cash,
I'm Watching These 6 Dividend Stocks For Big Announcements
07:55am, Sunday, 05'th Apr 2026
Dividend raises mean something right now.
Bank of America sees Eli Lilly's Foundayo as preferred oral GLP-1
12:57pm, Thursday, 02'nd Apr 2026
Eli Lilly and Co (NYSE:LLY) is entering the US market slightly ahead of schedule with its oral GLP-1 weight-loss therapy Foundayo, a move Bank of America says could expand the obesity market without c
GLP-1 wars: Lilly's FDA-approved oral weight-loss pill puts Novo Nordisk's Wegovy franchise under fresh pressure
08:20am, Thursday, 02'nd Apr 2026
Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter results Eli Lilly and Co (NYSE:LLY) has won FDA ap
Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison
08:00am, Thursday, 02'nd Apr 2026
Oral Wegovy demonstrated "significantly greater mean weight loss" than Lilly's rival pill Foundayo, which was approved this week, Novo Nordisk said Thursday. Novo's findings evaluated previously publi
Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independen
Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
03:12am, Thursday, 02'nd Apr 2026
Shares in Novo Nordisk (NYSE:NVO) held firm and edged higher in early trading on Thursday despite the US Food and Drug Administration approving a new once-daily weight-loss pill from rival Eli Lilly t
